Yan Yong-Xing, Liang Li-Zhen, Shen Yong-Hui, Li Peng, Zhong Chang-Yang
Department of Neurology, The Third hospital of Hangzhou, Hangzhou 310009, China.
Zhongguo Zhong Yao Za Zhi. 2012 Dec;37(23):3667-8.
To observe the clinical efficacy of Maixuekang capsule in reconvalescents of cerebral infarction and its impact on coagulation function.
One hundred and twenty cases of reconvalescents of cerebral infarction were randomly divided into treatment and control groups. The 50 cases in the control group were provided with conventional therapy, while the 70 cases in the treatment group were provided with the combination of conventional therapy and Maixuekang capsule for 3 months. Their neurological function and prothrombin time (PT), activated partial thromboplastin time (APTT) clotting enzyme time (TT), fibrinogen (Fib) were measured before and after treatment.
After the treatment, PT, APTT and TT were prolonged compared with those before the treatment in the treatment group (P<0.05), whereas Fib, neurological deficit scores decreased (P<0.01) and significantly different from the control group (P<0.05).
Maixuekang capsule is among safe and effective drugs in treatment of reconvalescents of cerebral infarction, and can improve the patient's coagulation state.
观察脉血康胶囊对脑梗死恢复期患者的临床疗效及其对凝血功能的影响。
将120例脑梗死恢复期患者随机分为治疗组和对照组。对照组50例给予常规治疗，治疗组70例在常规治疗基础上加用脉血康胶囊治疗3个月。分别于治疗前后测定两组患者的神经功能及凝血指标，包括凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、凝血酶时间（TT）、纤维蛋白原（Fib）。
治疗后，治疗组PT、APTT、TT较治疗前延长（P<0.05），Fib、神经功能缺损评分降低（P<0.01），且与对照组比较差异有统计学意义（P<0.05）。
脉血康胶囊是治疗脑梗死恢复期安全有效的药物之一，能改善患者的凝血状态。
